Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study.

ABSTRACT:

Background

The purpose of this study was to evaluate the safety, tolerability, and efficacy of milnacipran following a direct switch from duloxetine in fibromyalgia patients experiencing inadequate clinical response to duloxetine after receiving treatment for 6 weeks or longer.

Methods

This exploratory study included 107 patients with fibromyalgia who had been treated with duloxetine 60 mg/day for at least 4 weeks prior to enrollment. Following a 2-week open-label period on duloxetine, patients who had visual analog scale pain scores ≥ 40 and were dissatisfied with current treatment were randomized 4:1 to milnacipran 100 mg/day (n = 86) or placebo (n = 21) for 10 weeks of double-blind treatment. The small placebo group was included solely to blind the study and minimize expe

SUBMITTER: Bateman L 

PROVIDER: S-EPMC3643187 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature